** Lexicon Pharmaceuticals' LXRX.O shares rise 6.3% to 82 cents
** Co says it plans to cut about 60% of its workforce effective Dec. 31
** Co to shut down commercial operations and stop promotions for its approved heart failure treatment, Inpefa, but will continue production and supply for patients and existing prescribers
** Piper Sandler analysts say the Inpefa decision "removes capital constraints/overhang driving investor uncertainty"
** Says U.S. FDA noted deficiencies in LXRX's application seeking approval for the drug as an add-on treatment to insulin therapy for managing blood glucose levels in adults with type 1 diabetes and chronic kidney disease
** LXRX had 285 employees as of Mar 21, according to its latest annual report
** Including session's gains, stock has fallen 47.5% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。